Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy

Antiviral Therapy

Volumn 14, Issue 3, 2009, Pages 331-338

  Gingelmaier, Andrea ^a   Grubert, Thomas A ^b   Kost, Bernd P ^a   Setzer, Bernhard ^c   Lebrecht, Dirk ^c   Mylonas, Ioannis ^a   Mueller Hoecker, Josef ^a   Udo, Jeschke ^a   Hiedl, Stephan ^a   Friese, Klaus ^a   Walker, Ulrich A ^c,d  

^a UNIVERSITY OF MUNICH   (Germany)

^b Department of Obstetrics and Gynaecology ^*  (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTIRETROVIRUS AGENT; CYTOCHROME C OXIDASE; DIDANOSINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LACTIC ACID; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MITOCHONDRIAL DNA; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; SUCCINATE DEHYDROGENASE (UBIQUINONE); ZIDOVUDINE;

ADULT; ARTICLE; CELL ULTRASTRUCTURE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTRON MICROSCOPE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; LACTATE BLOOD LEVEL; MITOCHONDRIAL DNA DEPLETION; MITOCHONDRIAL TOXICITY; MITOCHONDRION; NEWBORN; PERINATAL DRUG EXPOSURE; PLACENTA; POLYMERASE CHAIN REACTION; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; SIDE EFFECT; WESTERN BLOTTING;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, MITOCHONDRIAL; ELECTRON TRANSPORT COMPLEX IV; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; LACTIC ACID; MITOCHONDRIA; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES;

EID: 67649194801     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005: 40:458-465.
2. Perinatal HIV Guidelines Working Group. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. (Updated 8 July 2008. Accessed 10 August 2009.) Available from http://aidsinfo.nih.gov/contentfiles/PerinatalGL_PDA.pdf
3. Chappuy H, Tréluyer JM, Jullien V, et al. Maternal-fetal transfer and amniotic fluid accumulation'of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48:4332-4336.
4. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084-1099.
5. Perinatal Safety Working Group. Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000; 25:261-268.
6. Venhoff N, Walker UA. Mitochondrial disease in the offspring as a result of antiretroviral therapy. Expert Opin Drug Saf 2006; 5:373-381.
7. Poirier MG, Divi RL, Al-Harthi L, et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 2003; 33:175-183.
8. Venhoff N, Setzer B, Melkaoui K, Walker UA. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 2007; 12:1075-1085.
9. Buchholz B, Beichert M, Marcus U, et al. German-Austrian recommendations for HIV-therapy in pregnancy and in HIV-exposed newborn - update 2Y05. Eur J Med Res 2006; 11:359-376.
10. Lebrecht D, Vargas-Infante YA, Setzer B, Kirschner J, Walker UA. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 2007; 45:72-79.
11. Benhammou V, Tardieu M, Warszawski J, Rustin P, Blanche S. Clinical mitochondrial dysfunction in uninfected children born to HIV-infected mothers following perinatal exposure to nucleoside analogues. Environ Mol Mutagen 2007; 48:173-178.
12. Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001; 15:1074-1075.
13. Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22:782-789.
14. Noguera A, Fortuny C, Muñoz-Almagro C, et al. Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals. Pediatrics 2004; 114:e598-e603.
15. Shiramizu B, Shikuma KM, Kamemoto L, et al. Placenta and cord blood mitochondrial DNA-toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. J Acquir Immune Defic Syndr 2003; 32:370-374.
16. Divi RL, Leonard SL, Kuo MM, et al. Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity. Environ Mol Mutagen 2007; 48:201-209.
17. Divi RL, Walker VE, Wade NA, et al. Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir. AIDS 2004; 18:1013-1021.
18. Cihlar T, Ray AS, Laflamme G. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther 2007; 12:267-272.
19. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43:278-283.
20. Bouhours-Nouet N, May-Panloup P, Coutant R, et al. Maternal smoking is associated with mitochondrial DNA depletion and respiratory chain complex III deficiency in placenta. Am J Physiol Endocrinol Metab 2005; 288: E171-E177.
21. Gerschenson M, Nguyen V, Ewings EL, et al. Mitochondrial toxicity in fetal Erythrocebus patas monkeys exposed transplacentally to zidovudine plus lamivudine. AIDS Res Hum Retroviruses 2004; 20:91-100.
22. Walker DM, Poirier MC, Campen MJ, et al. Persistence of mitochondrial toxicity in hearts of female B6C3F1 mice exposed in utero to 3′-azido-3′-deoxythymidine. Cardiovasc Toxicol 2004; 4:133-153.
23. McComsey GA, Kang M, Ross AC, et al. Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy. HIV Clin Trials 2008; 9:126-136.
24. Walker UA, Venhoff N, Koch EC, Olschewski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003; 8:463-470.
25. Bishop JB, Tani Y, Witt K, et al. Mitochondrial damage revealed by morphometric and semiquantitative analysis of mouse pup cardiomyocytes following in utero and postnatal exposure to zidovudine and lamivudine. Toxicol Sci 2004; 81:512-517.
26. Clark KM, Taylor RW, Johnson MA, et al. An mtDNA mutation in the initiation codon of the cytochrome c oxidase subunit II gene results in lower levels of the protein and a mitochondrial encephalomyopathy. Am J Hum Genet 1999; 64:1330-1339.